Fibrin

• 

  Subject Areas on Research

  • A Regenerative Cardiac Patch Formed by Spray Painting of Biomaterials onto the Heart. 
  • A comparative study of crosslinked and noncrosslinked fibrin from the major classes of vertebrates. 
  • A novel role for erythropoietin during fibrin-induced wound-healing response. 
  • A prospective, open-label, dose-escalating study of low molecular weight heparin during repeat vitrectomy for PVR and severe diabetic retinopathy. 
  • Ab interno sclerostomy with a high-powered argon endolaser. 
  • Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. 
  • Actions of thrombin in the interstitium. 
  • Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. 
  • Analyzing fibrin clot structure using a microplate reader. 
  • Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. 
  • Cell-based models of coagulation: a paradigm in evolution. 
  • Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII. 
  • Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro. 
  • Coagulopathy in COVID-19. 
  • Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery. 
  • Concentration of protein in fibrin fibers and fibrinogen polymers determined by refractive index matching. 
  • Correlation between erythrocyte CR1 reduction and other blood proteinase markers in patients with malignant and inflammatory disorders. 
  • Cross-linked fibrinogen dimers demonstrate a feature of the molecular packing in fibrin fibers. 
  • Cross-linking of fibrin by fibrin=stabilizing factor. 
  • D-dimer antigen: current concepts and future prospects. 
  • Dietary glycine inhibits angiogenesis during wound healing and tumor growth. 
  • Differential effects of cytochalasin B on platelet release, aggregation and contractility: evidence against a contractile mechanism for the release of platelet granular contents. 
  • Dynamic culture yields engineered myocardium with near-adult functional output. 
  • Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. 
  • Electron microscopy of fibrinogen, its plasmic fragments and small polymers. 
  • Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. 
  • Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. 
  • Emerging paradigms in arterial thrombosis. 
  • Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. 
  • Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. 
  • Fibrin assembly: a comparison of electron microscopic and light scattering results. 
  • Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. 
  • Fibrin directs early retinal damage after experimental subretinal hemorrhage. 
  • Fibrin modification by ionic and nonionic contrast media during cardiac catheterization. 
  • Fibrin specific peptides derived by phage display: characterization of peptides and conjugates for imaging. 
  • Fibrin-modulating nanogels for treatment of disseminated intravascular coagulation. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. 
  • Future alternatives to heparin: low-molecular-weight heparin and hirudin. 
  • HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. 
  • Heart regeneration in zebrafish. 
  • High dose factor VIIa improves clot structure and stability in a model of haemophilia B. 
  • Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. 
  • Human mononuclear phagocyte transglutaminase activity cross-links fibrin. 
  • Hyaluronic acid and fibrin hydrogels with concentrated DNA/PEI polyplexes for local gene delivery 
  • Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. 
  • Immune responses to coiled coil supramolecular biomaterials. 
  • In vitro preparation of nonenzymatically glucosylated human transferrin, alpha 2-macroglobulin, and fibrinogen with preservation of function. 
  • In-vivo response to free electron laser incision of the rabbit cornea. 
  • Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. 
  • Intraocular injection of recombinant hirudin to prevent experimental postoperative fibrin. 
  • Intravitreal clearance of tissue plasminogen activator in the rabbit. 
  • Lateral packing of protofibrils in fibrin fibers and fibrinogen polymers. 
  • Lipoprotein (a) regulates plasmin generation and inhibition. 
  • Low dose heparin therapy: in vitro verification of antithrombotic effect. 
  • Low-dose intraocular tissue plasminogen activator for treatment of postvitrectomy fibrin formation. 
  • Macrophage embedded fibrin gels: an in vitro platform for assessing inflammation effects on implantable glucose sensors. 
  • Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin. 
  • Metabolic requirements of contractile force generation in platelet rich plasma - a rheological study. 
  • Mitomycin-induced hemolytic-uremic syndrome. 
  • Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. 
  • Mojave toxin in venom of Crotalus helleri (Southern Pacific Rattlesnake): molecular and geographic characterization. 
  • Molecular diffusion in tissue-engineered cartilage constructs: effects of scaffold material, time, and culture conditions. 
  • Nanosilver composite pNIPAm microgels for the development of antimicrobial platelet-like particles. 
  • Off-the-shelf, heparinized small diameter vascular graft limits acute thrombogenicity in a porcine model. 
  • Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases. 
  • Platelet and fibrin modification by radiographic contrast media. 
  • Platelet-like particles improve fibrin network properties in a hemophilic model of provisional matrix structural defects. 
  • Postoperative fibrin formation and visual outcome after pars plana vitrectomy. 
  • Preferential motor reinnervation in the mouse: comparison of femoral nerve repair using a fibrin sealant or suture. 
  • Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction. 
  • RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter-to-the-Editor by Dr Wada. 
  • Recombinant hirudin for prevention of experimental postoperative intraocular fibrin. 
  • Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery. 
  • Red versus white thrombi in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: clinical and angiographic outcomes. 
  • Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. 
  • Risk factors for postvitrectomy fibrin formation. 
  • Self-assembling peptide-polymer hydrogels designed from the coiled coil region of fibrin. 
  • Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. 
  • Strong Binding of Platelet Integrin αIIbβ3 to Fibrin Clots: Potential Target to Destabilize Thrombi. 
  • Structure of the fibrin protofibril. 
  • Subunit structure of fragment D from fibrinogen and cross-linked fibrin. 
  • The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. 
  • The biochemistry of haemostasis. 
  • The effect of fibrin-stabilizing factor on the subunit structure of human fibrin. 
  • The effect of plasmin on the subunit structure of human fibrin. 
  • The effect of vascular endothelial growth factor (VEGF) presentation within fibrin matrices on endothelial cell branching 
  • The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. 
  • The hemodynamics of thrombus formation in arteries. 
  • The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. 
  • The pathology of vitreous hemorrhage. II. Ultrastructure. 
  • The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor). 
  • Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis. 
  • Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. 
  • Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm? 
  • Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. 
  • Throwing out the thromboemboli. 
  • Tissue factor and fibrin in tumor angiogenesis. 
  • Tissue factor, thrombin, and cancer. 
  • Tissue plasminogen activator for postvitrectomy fibrin formation. 
  • Towards understanding the effect of fibrinogen interactions on fibrin gel structure. 
  • Transient Bacteremia Promotes Catheter-Related Central Venous Thrombosis through Neutrophil Extracellular Traps. 
  • Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. 
  • Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator. 
• 

  Keywords of People

  • Hoffman, Maureane, Professor of Pathology, Integrative Immunobiology